Form 4 for NAGE Niagen Bioscience, Inc.
Accepted 2025-11-17 00:00:00 ET · period of report 2025-11-14 · accession 0001834681-25-000005 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-11-17 | 2025-11-14 | NAGE | Pamir Ozan | CFO | P - Purchase | $6.81 | +4,465 | 7,372 | +154% | +$30.4K | |
| I | 2025-11-17 | 2025-11-14 | NAGE | Pamir Ozan | CFO | P - Purchase | $6.85 | +2,220 | 2,220 | New | +$15.2K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-11-14 | P | A | 4,464.96 | $6.81 | 7,372.16 | D The reported securities are held by the reporting person's spouse. | — | — | (F1) The weighted average purchase price for the transaction reported was $6.81, and the range of prices were between $6.7975 and $6.82, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased at each separate price within the range above will be provided. |
| 2 | Common | Common Stock | 2025-11-14 | P | A | 2,220.44 | $6.85 | 2,220.44 | I | — | — |